Article

Exploiting cross-amyloid interactions to inhibit protein aggregation but not function: nanomolar affinity inhibition of insulin aggregation by an IAPP mimic.

Laboratory of Peptide Biochemistry, Center for Integrated Protein Science München, Technische Universität München, An der Saatzucht 5, 85350 Freising-Weihenstephan, Germany.
Angewandte Chemie International Edition (Impact Factor: 13.73). 02/2008; 47(37):7114-8. DOI:10.1002/anie.200801499
Source: PubMed
0 0
 · 
0 Bookmarks
 · 
44 Views
  • Source
  • Source
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments. To classify the compounds, a concept is proposed assigning drugs to 19 categories according to their mechanism(s) of action, in particular drugs interacting with receptors, enzymes, ion channels, nerve growth factors, re-uptake transporters, antioxidants, metal chelators, and disease modifying drugs, meaning small molecules, vaccines, and monoclonal antibodies interacting with amyloid-β and tau. For drugs, whose mechanism of action is not known, they are either classified according to structure, e.g., peptides, or their origin, e.g., natural products. The review covers the evolution of research in this field over the last 25 years.
    Journal of Alzheimer's disease: JAD 11/2012; · 4.17 Impact Factor